Abstract
The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.
| Original language | English |
|---|---|
| Pages (from-to) | 831 - 838 |
| Number of pages | 8 |
| Journal | Expert Review of Cardiovascular Therapy |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2012 |